Research in traumatic brain injury (TBI) is challenging for several reasons; in particular, the heterogeneity between patients regarding causes, pathophysiology, treatment, and outcome. Advances in basic science have failed to translate into successful clinical treatments, and the evidence underpinning guideline recommendations is weak. Because clinical research has been hampered by non-standardised data collection, restricted multidisciplinary collaboration, and the lack of sensitivity of classifi cation and effi cacy analyses, multidisciplinary collaborations are now being fostered. Approaches to deal with heterogeneity have been developed by the IMPACT study group. These approaches can increase statistical power in clinical trials by up to 50% and are also relevant to other heterogeneous neurological diseases, such as stroke and subarachnoid haemorrhage. Rather than trying to limit heterogeneity, we might also be able to exploit it by analysing diff erences in treatment and outcome between countries and centres in comparative eff ectiveness research. This approach has great potential to advance care in patients with TBI.
Introduction
Traumatic brain injury (TBI) is a serious public health problem with an estimated annual incidence of up to 500 cases per 100 000 population in the USA and Europe. 1, 2 A recent population-based study 3 from New Zealand reported an annual incidence of 790 per 100 000 personyears. In low-income and middle-income countries most injuries result from road traffi c incidents; in high-income countries, falls are now a more frequent cause of TBI and commonly occur in older patients. TBI is a major cause of death and disability, leading to great personal suff ering for patients and relatives and huge direct and indirect costs to society. In the USA these annual costs are estimated at more than US$76·5 billion. 4 Despite the magnitude of the socioeconomic and medical problem posed by TBI, the strength of evidence underpinning treatment recommendations is low. Since the fi rst publication of guidelines for management of severe TBI in 1996, 5 strong evidence in support of treatment recommendations has not been forthcoming. Con ventional approaches to clinical TBI research have been reductionist, attempting to isolate a single factor for treatment. 6 These approaches have ignored the heterogeneity of TBI in terms of causes, pathophysiology, treatment, and outcome. This heterogeneity makes research in TBI particularly challenging, and might partly explain why many randomised clinical trials have not had statistically signifi cant positive results. 7 This aspect is being addressed in two ways. First, by applying novel methods to deal with the heterogeneity of TBI; for example, combining covariate adjustment with an ordinal approach to analysis as proposed by the International Mission on Prognosis and Analysis of randomized Controlled Trials in TBI (IMPACT) studies off ers the potential to increase the statistical effi ciency by up to 50%. 8 Second, rather than attempting to limit heterogeneity from care paths, treatments, and outcomes, we can exploit it by using comparative eff ectiveness research. Comparative eff ectiveness research is the generation and synthesis of evidence that compares the benefi ts and harms of alternative methods to prevent, diagnose, treat, and monitor a clinical condition, or to improve the delivery of care. The purpose of this research is to assist consumers, clinicians, purchasers, and policymakers to make informed decisions that will improve health care at both the individual and population levels. 9 Comparative eff ective ness research is broadly defi ned and can include pragmatic clinical trials. One approach is to make use of existing diff erences in treatment and outcome between countries and centres, with the aim of identifying best practices. Modern computational techniques and the availability of robust risk adjustment models allow such approaches, off ering the potential to acquire high quality evidence in observational studies with greater generalisability. 7 In this Personal View we summarise the results of the IMPACT studies and discuss the potential of comparative eff ectiveness research to provide evidence in support of care paths and treatment recommendations in TBI. This discussion is pertinent because large observational studies in TBI will soon be initiated in the context of an international collaboration established by the European Commission, the US National Institute of Neurological Disorders and Stroke (NIH-NINDS), and the Canadian Institutes of Health Research (CIHR).
The IMPACT studies Background
The IMPACT studies, funded by NIH-NINDS, were initiated in 2003. For 10 years this international, multidisciplinary study group has addressed methodological issues to improve the design and analysis of clinical trials in TBI. The IMPACT investigators were initially granted access to 11 large datasets of clinical trials (n=8) and observational studies (n=3) undertaken in North America and Europe. 10 Permission to access the datasets was obtained from principal investigators and, when appropriate, sponsoring companies. During the project, additional studies were added and collaborations were Personal View developed with the MRC CRASH trial investigators and the TARN registry. 11, 12 The available datasets were used to test and validate new approaches to trial design and analysis. As the project developed, three main directions of research evolved: fi rst, standardisation of data collection; second, prognostic analysis and development of prognostic models; and third, improvements in the design and analysis of randomised clinical trials.
Standardisation of data collection
Merging of individual patient data for analysis across the constituent studies of the IMPACT database proved to be a major challenge. Not only did data fi eld names and coding diff er, but also the structures of the datasets were complex and the documentation poor. This emphasised the importance of consensus on a basic set of core variables to be collected in TBI studies, with agreement on appropriate defi nitions, fi eld names, and coding. Obtaining such agreement would expedite study designs, allow individual patient data analysis across studies, and reduce costs to funding agencies and pharmaceutical companies. From this perspective the IMPACT investigators initiated a process of standardisation of data collection in TBI studies. This process was taken forward in the context of an international and interagency initiative towards "an integrated approach to research and psychological health and traumatic brain injury" in the USA. 13 This initiative proposed common data elements and included proposals for defi nitions and coding of demographic characteristics, basic clinical data, biomarkers, neuroimaging, and outcomes. The original intent was to focus on the most important variables for characterisation of TBI popu lations, including established prognostic indicators. The process was consensus-driven with multidisciplinary input from a broad range of experts, from emergency medicine to rehabilitation and late outpatient care.
The Working Group on Demographics and Clinical Assessments recognised that the required level of detail for coding a variable can vary with the aim of a specifi c study. Thus, up to three versions for coding data elements were developed: a basic, an advanced, and an extended format with the greatest level of detail. The coding of these variables was such that more detailed coding could always be collapsed into the basic version, thus enabling comparisons across studies. 14, 15 In a version 2, the common data elements were refi ned. 16 This revised version also addressed variables for epidemiological, postacute care, and outcomes research. As a consequence, the number of variables has expanded substantially, resulting in a less user-friendly presentation and, regrettably, the initial focus on the most important elements has partly been lost. A broad discussion would seem appropriate as to whether the common data elements should be focused on the most important variables to be collected in all studies or that a more inclusive approach should be taken in the context of a Personal View data dictionary. Version 2 of the common data elements represents a hybrid format of these approaches in which the most relevant variables for the diff erent domains of TBI research are designated as core or basic. The TBI common data elements eff ort is an evolving process, and recent studies that have implemented the common data elements, such as TRACK-TBI, 17 will probably provide data to resolve some of these issues for the anticipated version 3. This revision should be informed by experience and evidence, rather than being based on consensus.
Prognostic analysis and development of models
Diff erences in patient population (casemix) can confound comparison of results between studies. In randomised controlled trials, the process of randomisation seeks to achieve balance between treatment groups. However, an imbalance in cumulative prognostic risk between treatment groups can occur, despite only minor differences in individual characteristics. Quantifi cation of the initial prognostic risk is therefore highly relevant. Many studies have reported on associations between predictors and outcome after TBI, but most have focused on univariate analyses in small sample sizes. The few studies that integrated predictors into a prognostic model to predict outcome on an individual patient basis had many methodological shortcomings, in particular the absence of external validation. 18, 19 The IMPACT database allowed extensive prognostic analyses on large numbers of patients (n>8000). Unique features included a systematic approach to the adjusted analyses of predictors, 20 non-linear analysis of continuous predictors, and proportional odds analysis of the Glasgow outcome scale, rather than use of a dichotomised analysis such as survival or unfavourable versus favourable outcome. 20 of the prognostic strength of the most important predictors for outcome in TBI in more patients, based on the 2013 version of the IMPACT database. The importance of adjustment for other predictors in multivariable analysis is well illustrated by the prognostic strength of cause of injury. Cause of injury was strongly associated with outcome in univariate analysis, with falls having a signifi cantly higher risk of poor outcome than road traffi c incidents or other causes. However, after adjustment for age and other predictors in multivariable analysis, the association between cause of injury, specifi cally the occurrence of a fall, and outcome that was seen in univariate analysis is no longer found. Thus, the eff ect of cause of injury is confounded by the age of patients sustaining falls. Analysis of blood pressure emphasises the importance of continuous non-linear analysis of continuous predictors both low and high blood pressures were related to poor outcome, in a U-shaped relation (fi gure 1). This relation would not have been observed if one cutoff for blood pressure had been chosen.
The most important predictors of outcome were included in three prognostic logistic regression models 
Multivariable logistic regression analysis was done on the association between the prognostic factor of interest with and without adjustment for the core predictors: age, GCS motor score, and pupillary reactivity. The numbers in the adjusted analysis column show availability of each covariate in adults with non-missing outcome in the overall dataset. In the adjusted analyses missing values for pupillary response were replaced by imputed values. 22 For the continuous predictors with a linear relation to outcome, the odds ratios were scaled so that they correspond to change from the 25th percentile to the 75th percentile (IQR). The IQR is reported for each continuous variable. An odds ratio greater than 1 for a continuous prognostic factor indicates that the risk of a poor outcome increases as the variable increases over the IQR. GCS=Glasgow coma scale. SAH=subarachnoid haemorrhage. EDH=epidural haematoma. SDH=subdural haematoma. *Adjusted for GCS motor score and pupillary response. †Adjusted for age and pupillary response. ‡Adjusted for age and GCS motor score. Predictions from the models for individual patients can be obtained from the IMPACT website . Specifi cally, we note that the simple core model (including age, motor score, and pupillary reactivity) contains most of the prognostic information. These models were initially validated both internally and externally in collaboration with the CRASH trial investigators, 23 and thereafter in various other datasets (table 2) . 25, [31] [32] [33] [34] Although missing data should be avoided as far as possible in high-quality studies, this issue does occur and has to be dealt with. Multiple imputation was used to deal with missing covariates. Such imputation is deemed more effi cient than complete case analysis, in which cases with incomplete data are dropped. 35, 36 Discrimination was assessed by the area under the receiver operating characteristic curve (AUC) and was typically around 0·7-0·8 in ten external validation studies. The variability in discriminatory performance was mainly related to variation in the casemix in the validation sets, with better performance in more observational studies on more heterogeneous popu lations, such as TARN and POCON (table 2) . 27, 31, 37 This extensive validation illustrates the robustness of the IMPACT models and their generalisability across various settings. Nevertheless, several limitations in the use and interpretation of the IMPACT models should be acknowledged. First, as in any prognostic model, the output of the calculation remains a probability estimate with an inherent degree of uncertainty. Thus, particular care should be taken in the interpretation of prognostic estimates in individual patients. Second, the focus of the IMPACT prognostic analysis was the establishment of baseline prognostic risk and the studies did not include dynamic predictions, adding new information as it becomes available over the course of the disease process. Third, the IMPACT studies were limited by the selection and detail of predictors that had been collected in previous studies. Some, possibly relevant, predictors could not be analysed in adequate detail owing to the low number of patients in which these had been collected. Examples include details of coagulation status and the presence and severity of extracranial injuries. 33, 38 Fourth, the IMPACT dataset did not include patients with mild TBI, and the IMPACT models are consequently not valid for this condition. Despite the fact that up to 95% of TBIs are mild, only one prognostic model has been developed specifi cally for mild TBI. 39 Finally, a further possible selection bias might have been introduced by the lack of population-based studies. This risk is however regarded as low because the focus of the IMPACT prognostic analysis was more on patients with severe and moderate TBI. Population-based studies are more relevant to mild TBI because most of these patients are not seen in the hospital setting.
Improving the design and analysis of randomised controlled trials
In TBI, nearly all randomised clinical trials have attempted to decrease heterogeneity by applying strict enrolment criteria or by targeting patients with an intermediate prognosis at randomisation. A contrasting approach was followed in the CRASH megatrial, in which large numbers of participants were predicted to overcome problems caused by prognostic heterogeneity and increase generalisability. The relative effi cacy of these approaches was explored systematically in the IMPACT project. Simulation studies showed that exclusion of patients with an extreme prognosis-by the use of strict enrolment criteria or by prognostic targeting-indeed increases statistical power. 40 However, as a result of this strict selection many patients are excluded from study participation, 41 which limits the generalisability of the results. Moreover, strict selection will reduce the recruitment rate, thereby prolonging study duration. Benefi cial eff ects in terms of increased statistical power of strict selection need to be balanced against negative eff ects on recruitment. On the assumption of a uniform treatment eff ect, this balance has been unfavourable for the execution of studies with such restrictive enrolment criteria. 40 Despite the fact that conditional estimation of treatment eff ects, also by non-normal regression models such as logistic or Cox regression models, is more powerful than unadjusted estimation, [42] [43] [44] fairly few 
Personal View
randomised clinical trials have dealt with the problem of heterogeneity by adjusting the treatment eff ect for important predictors of outcome using covariate adjustment. Simulation studies with TBI trial data showed that covariate adjustment for seven strong predictors of outcome increased statistical effi ciency up to 30% in more heterogeneous populations of observational surveys and up to 16% in trial populations that initially used stricter enrolment criteria. 40 In a reanalysis of the CRASH trial data, 45 covariate adjustment for age, Glasgow coma scale motor score, and pupillary reactivity reduced the required sample size by 21% to obtain the same statistical power compared with the unadjusted analysis. Covariate adjustment should be prespecifi ed and include established strong predictors for outcome. 42 We note that risk adjustment models might need to be updated as newer prognostic information becomes available.
When testing the effi cacy of a new therapy the aim is to prove that the new treatment yields better results than placebo treatment or conventional management, in other words that patients will have a better outcome than expected. The primary outcome measure in most randomised clinical trials for TBI is the Glasgow outcome scale or its extended version. 46, 47 It is common practice to dichotomise this scale into favourable versus un favourable outcomes. However, the practice of dichotomisation is clinically unattractive and statistically ineffi cient. The prognosis of patients at the extreme ends of the outcome distribution can be either so good that they will almost inevitably achieve a favourable outcome, even without the benefi ts of an eff ective therapeutic intervention, or so poor that it is unlikely that even an eff ective intervention would improve their outcome to such an extent that it would move from being unfavourable to favourable. Moreover, focusing only on one specifi c split of the outcome scale ignores the fact that other transitions of the outcome are clinically relevant. We considered two novel approaches to ordinal effi cacy analysis: the sliding dichotomy approach and proportional odds regression (fi gure 2). With the sliding dichotomy approach, the point of the dichotomy is diff erentiated according to the baseline prognostic risk. For example, for patients with poor prognosis, survival might be most relevant, whereas in those with a good prognosis any outcome worse than good recovery might be deemed unfavourable. Proportional odds regression considers all possible ways in which the ordinal scale can be dichotomised, assuming that the odds ratio for a better versus worse outcome is identical wherever the scale is dichotomised (the proportional odds assumption). Conceptually, the model combines all potential splits to estimate an overall eff ect measure: the common odds ratio. This common odds ratio can be interpreted as the odds for a shift in outcome across the full ordinal scale. 48 Simulation studies with the IMPACT database showed that ordinal approaches to the effi cacy analysis reduced the sample sizes required by 23-30% compared with the traditional dichotomised analysis. 21 These gains were consistent across studies and, remarkably, also remained if the proportional odds assumption was violated. Applying covariate adjustment together with ordinal analysis reduced the sample size requirements by up to 50%. These fi ndings were confi rmed in the CRASH trial: 49 combining ordinal analysis with covariate adjustment increased statistical effi ciency by about 50% 
and statistically signifi cant eff ects were already present after enrolment of around 50% of the population. 49 The combined results of the simulation studies and empirical proof of eff ectiveness of the IMPACT recommendations in CRASH provide strong support to incorporate these approaches in the design of new clinical trials (panel).
Perspectives on future research Standards for data collection and prognostic research
The IMPACT studies illustrate how international and multidisciplinary collaboration can accelerate research and how methodological research can lead directly to improved clinical research. The recent institution of the International Initiative for Traumatic Brain Injury Research (InTBIR) as a collaboration between funding agencies (the European Commission, NIH-NINDS, and CIHR) represents a milestone accomplishment and provides a platform for global collaboration in TBI research. 50, 51 The concepts developed by the IMPACT study group are being taken forward. Use of common data elements is currently required in all observational studies and trials in TBI that are funded by NIH-NINDS. A recent call by the European Commission also mandated use of core common data elements. 52 This adoption of common data elements by funding agencies might be expected to assist with comparisons between studies, meta-analyses of individual patient data across studies, and, importantly, will reduce costs in the design of case report forms for new studies. From a global perspective, the generalisability for use of the common data elements across diff erent settings and empirical experience in their use should form the basis for Panel: Recommendations for design and analysis of randomised controlled trials in traumatic brain injury 8 • Details of the major baseline prognostic characteristics should be provided in every report of a study; in trials they should be diff erentiated per treatment group. We also advocate the reporting of a summary of the baseline prognostic risk as determined by validated prognostic models.
• Inclusion criteria should be as broad as is compatible with the current understanding of the mechanisms of action of the intervention being evaluated. This approach will maximise recruitment rates and improve the generalisability of the results.
• The statistical analysis should incorporate (prespecifi ed) covariate adjustment to mitigate the eff ects of heterogeneity.
• The statistical analysis should use an ordinal approach, based on either sliding dichotomy or proportional odds methods. 
B Sliding dichotomy approach

Figure 2: Approaches to analyse the Glasgow outcome scale as the primary outcome measure in randomised controlled trials of traumatic brain injury The traditional approach (A) to effi cacy analysis is to dichotomise the Glasgow outcome scale into unfavourable outcomes (dead [D], vegetative state [VS], or severe disability [SD]) versus favourable outcomes (moderate disability [MD] or good recovery [GR])
. The proportions of patients with an unfavourable outcome in the treatment and placebo groups are compared by calculating an odds ratio (OR) with logistic regression analysis. With the sliding dichotomy approach (B), the study population is fi rst subdivided in (for example, three) equally large prognostic risk groups. For each of the risk groups, the point of the dichotomy of the Glasgow outcome scale is based on the baseline prognostic risk (eg, for patients in the good prognostic risk group, only good recovery is judged a favourable outcome). A pooled odds ratio is calculated, which can be interpreted as the summary measure for having a better outcome than expected. With the proportional odds approach (C), the population is not subdivided. The proportional odds model considers every possible way the Glasgow outcome scale can be dichotomised, assuming that the odds ratio for a better versus a worse outcome is similar wherever the scale is dichotomised (the proportional odds assumption). The common odds ratio can be interpreted as a summary measure for the shift in outcome across the full scale.
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further refi nements where compromises might need to be made between international generalisability and a national or local focus. The diff erentiation of coding into three levels of detail might provide opportunities for harmonisation of these two perspectives. Importantly, the common data elements should be presented in a user-friendly format.
The IMPACT prognosis studies have been instrumental in developing and setting standards for prognostic research in TBI. The predictive eff ects of many known prognostic variables have been confi rmed in much larger numbers than before, and novel predictors have been identifi ed. The development of the IMPACT prognostic models for severe and moderate TBI has provided opportunities to summarise the baseline prognostic risks in study populations and can be used as robust risk adjustment models. They have already been widely adopted in TBI research. 53 A major limitation is that these models were not developed for mild TBI. The CRASH prognostic models 54 included patients with milder injuries in their development and might consequently have broader generalisability across the range of severity. Prognostic models should never be thought of as fi nal, but will need continuous evaluation and validation. In this context the added value of new predictors should be taken into consideration. New candidate predictors would include gene signatures, biomarkers, coagulation parameters, and the presence of systemic injuries. The application of prognostic models in TBI is broader than clinical trial design and might be used towards classifi cation and benchmarking of the quality of healthcare delivery in TBI. 53 
Dealing with heterogeneity in clinical trials
The IMPACT recommendations for trial design have also been widely adopted. The Pharmos dexanabinol trial 29 was one of the fi rst in TBI to use covariate adjustment and proportional odds approaches in the effi cacy analysis. Since then, many completed and ongoing studies have adopted (parts of) the IMPACT recommendations. These studies include the DECRA trial on decompressive craniectomy in patients with diff use traumatic brain injury 55 and the ongoing EuroTherm (therapeutic hypothermia for TBI; ISRCTN 34555414) and the SyNAPSe (NCT01143064) and PROTECT III (NCT00822900) trials of progesterone for severe TBI.
Prognostic heterogeneity of patient populations does not only apply to TBI, but also to other neurological diseases (eg, ischaemic stroke, subarachnoid haemorrhage, intracerebral haemorrhage, and Guillain-Barré syndrome) and to other specialties. 42, [56] [57] [58] Methods to deal with heterogeneity in randomised controlled trials are essential for all these disciplines. In subarachnoid haemorrhage, the example of IMPACT is being followed by the Subarachnoid Hemorrhage International Trialists (SAHIT) data repository aiming to optimise the design and analysis of phase 3 trials in aneurysmal subarachnoid haemorrhage. 59 As in TBI, most large randomised controlled trials in acute ischaemic stroke have been neutral. 60 Stroke and TBI populations both have substantial prognostic heterogeneity, and an ordinal outcome measure is generally used (such as the modifi ed Rankin scale), which is often dichotomised for analysis. 61, 62 A recent report advises tailoring the analysis of the treatment eff ect to each individual trial, based on how the intervention under study is most likely to modify the distribution of outcomes; the ordinal analysis should be preferred over the traditional dichotomy, and covariate adjustment should be used. 63 The results of the SCAST, 64 IST-3, 65 and INTERACT2 66 stroke trials were only signifi cant when ordinal analysis was used. Several acute stroke trials have been published that have used diff erent aspects of the method described in the IMPACT recommendations. [67] [68] [69] [70] [71] Other ongoing stroke trials, such as STASH (statins for subarachnoid haemorrhage; NCT00731627), EuroHYP (hypothermia for acute ischaemic stroke; NCT01833312), MR CLEAN (endovascular treatment for acute ischaemic stroke; EudraCT 2009-017315-15), and others, plan to adopt parts of the recommendations.
Heterogeneity in comparative eff ectiveness research
We should recognise that many other issues (including defi ciencies in preclinical studies and early clinical investigation, as well as uncertainty in time windows and dosing) than heterogeneity have contributed to the disappointments in clinical trials. These aspects have not been addressed by the IMPACT study group, but have been previously reviewed in detail. [72] [73] [74] Neither have the IMPACT studies addressed the problem of heterogeneity related to physiological mechanism. Early mechanistic endpoints, which can serve as intermediate outcomes in trials, are still lacking. We further recognise that it will be impossible to mount a suffi cient number of adequately powered clinical trials to address all existing uncertainties in the management of TBI. Major advances in the care of patients with TBI have not come from clinical trials, but rather from observational studies and guideline developments. 7 Randomised controlled trials are not the only source of high-quality evidence to support practice recommendations. Alternative designs can be considered in a comparative eff ectiveness research framework.
Comparative eff ectiveness research is not new to TBI. Studies that compared treatment and outcome between centres in the 1980s would currently qualify as comparative eff ectiveness research. 75, 76 Several features of TBI favour comparative eff ectiveness research approaches. First, there are large between-centre diff erences and betweencountry diff erences in manage ment and outcome. In the IMPACT studies, analysing 9578 patients with moderate or severe TBI from 265 centres, we found a 3·3-fold diff erence in the odds of having an unfavourable outcome at 6 months between very good and very poor centres Personal View (2·5 vs 97·5 percentile) after adjustment for chance eff ects and for diff erences in casemix. 77 In CRASH diff erences were even larger, with a 6·6-fold between-centre diff erence in 14-day mortality and a 15-fold diff erence between countries. 78 Second, robust risk adjustment models, specifi c for TBI, are available to adjust for diff erences in major prognostic factors (casemix). Third, advanced statistical methods, including random eff ect models, have been fi eld-tested for TBI. 79 Comparative eff ectiveness research off ers opportunities to exploit the existing heterogeneity and diff erences between countries, centres, and patients in TBI to identify best practices. 7, 80 This approach needs highquality contemporaneous observational data to form the basis for comparative eff ectiveness research calls recently published in the European Commission Seventh Framework programme (FP7) and US National Institutes of Health (NIH) programmes. Recent data are important because, although methods for comparative eff ectiveness research are available, large-scale observational studies in TBI date back at least 20 years. 81 These calls will lead to improved characterisation of TBI and identifi cation of the most eff ective clinical interventions. Improved characterisation will assist personalised medicine approaches, as recently advocated by the National Academy of Science. 82 Phenotypic heterogeneity might interact critically with genetics, and exploring this possibility will need studies with large patient numbers. Novel information will come forward about disease processes, treatment, outcome, and prognosis in TBI, while the establishment of biorepositories for neuroimaging, genetics, and biomarkers will ensure opportunities for future research, including legacy research. Data-sharing policies will need to be established to encourage academic productivity and to accelerate TBI research. Table 3 summarises initiatives currently being developed within the context of InTBIR. Every initiative has a diff erent focus and, although individual analysis is expected to yield important contributions, the major benefi t will most likely result from integration of analyses across studies.
The establishment of InTBIR marks a shift in TBI research towards international and multidisciplinary collaborations, which bridge the traditional disconnection between acute and postacute research. We further note a shift from current reduction istic approaches in clinical research towards broad approaches with increased generalisability. We note, however, that randomised clinical trials remain the preferred approach for evaluation of effi cacy of novel treatment approaches and hope that the design of those trials will be aff ected by the results from the IMPACT studies, such as to optimise assessment of treatment eff ects.
Conclusions
The landscape of TBI research is changing. 45 Broadbased, sustainable, multidisciplinary, and international approaches are needed to address the complexity of Weaknesses of previous preclinical studies include poor design, use of experimental models and paradigms that fail to incorporate key elements germane to severe TBI in human beings, insuffi cient preclinical testing before proceeding into clinical trials, insuffi cient attention to brain penetration and pharmacokinetics in clinical studies, as well as publication bias for positive results. Methodological challenges in clinical trials, in particular challenges posed by the inherent heterogeneity of the patient population, have been addressed in the IMPACT studies. These have resulted in recommendations that have the potential to increase statistical effi ciency by up to 50%. This is a major advance, off ering improved chances to show effi cacy of new treatments in the context of randomised controlled trials. The IMPACT recom mendations have broad applicability, and principles of the recommendations are also being applied to the study of stroke and subarachnoid haemorrhage. International consensus on standardisation of data collection is being sought in the development of common data elements that will increase comparability between studies and metaanalyses of individual patient data across studies. Reductionist approaches originating from traditional research paradigms in which single factors are isolated and targeted are slowly being replaced by more holistic approaches that are more representative of the clinical situation. The potential of these approaches is now being recognised by funding agencies as evidenced by recent calls in the European Commission FP7 and NIH programmes. Improved clinical trial methods and exploitation of the heterogeneity of TBI in the context of comparative eff ectiveness research holds great promise for advancing the care of patients with TBI.
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